logo
logo

Xnk Therapeutics Raises Sek 132 Million To Accelerate Growth

Mar 29, 2022•over 3 years ago

Amount Raised

kr132 Million

Flemingsberg

Description

XNK Therapeutics AB ("XNK") today announced it has secured a private placement of SEK 132 million, to existing and new investors, led by Flerie Invest AB. The purpose of the issue is primarily to finance the company's clinical development in multiple myeloma and other indications.

Company Information

Company

Xnk Therapeutics Ab

Location

Flemingsberg, Stockholms län, Sweden

About

XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company is at the forefront of the development of autologous NK cell-based products using its proprietary technology platform. The company's platform technology and lead investigational candidate drug was developed specifically to target cancers, including settings where allogeneic cell products are not readily applicable. The Company's objective is for its investigational candidate drug and proprietary platform technology to constitute key components in the cancer treatments of tomorrow. XNK Therapeutics is headquartered in Stockholm, Sweden. For more information, please visit www.xnktherapeutics.com.

Related People

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech